Agios Pharmaceuticals (NASDAQ:AGIO) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16), Bloomberg Earnings reports. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue for the quarter was down 56.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.34) earnings per share.

Agios Pharmaceuticals (AGIO) opened at $76.53 on Wednesday. The stock has a market capitalization of $4,285.58, a PE ratio of -12.21 and a beta of 2.12. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $82.96.

In related news, insider Carman Alenson sold 2,150 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $75.00, for a total value of $161,250.00. Following the completion of the transaction, the insider now directly owns 2,150 shares in the company, valued at approximately $161,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David P. Schenkein sold 23,572 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $81.09, for a total value of $1,911,453.48. Following the completion of the transaction, the chief executive officer now owns 23,572 shares of the company’s stock, valued at $1,911,453.48. The disclosure for this sale can be found here. Insiders have sold a total of 183,114 shares of company stock valued at $13,866,025 over the last 90 days. Corporate insiders own 5.43% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its position in shares of Agios Pharmaceuticals by 40.8% in the 2nd quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 2,648 shares during the period. Ameriprise Financial Inc. grew its position in shares of Agios Pharmaceuticals by 21.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock valued at $2,572,000 after purchasing an additional 8,965 shares during the period. Northern Trust Corp grew its position in shares of Agios Pharmaceuticals by 31.3% in the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock valued at $11,977,000 after purchasing an additional 55,560 shares during the period. Alps Advisors Inc. grew its position in shares of Agios Pharmaceuticals by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 47,473 shares of the biopharmaceutical company’s stock valued at $3,169,000 after purchasing an additional 3,962 shares during the period. Finally, Brown Advisory Inc. grew its position in shares of Agios Pharmaceuticals by 8.5% in the 3rd quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock valued at $19,433,000 after purchasing an additional 22,736 shares during the period. Institutional investors and hedge funds own 82.74% of the company’s stock.

AGIO has been the subject of a number of research reports. Oppenheimer reiterated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Finally, BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $77.64.

WARNING: “Agios Pharmaceuticals (AGIO) Issues Earnings Results, Misses Expectations By $0.16 EPS” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/02/14/agios-pharmaceuticals-agio-issues-earnings-results-misses-expectations-by-0-16-eps.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.